Although the financial implications of Elan's and Biogen Idec's shock withdrawal from the market of the highly promising multiple sclerosis drug Tysabri were immediate and dramatic, it could have long-term consequences on the whole class of drug as companies developing drugs with a similar mechanism of action as Tysabri had to suspend their trials.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Related links
Related links
Related links in Nature Research
Related external links
Rights and permissions
About this article
Cite this article
Sheridan, C. Tysabri raises alarm bells on drug class. Nat Biotechnol 23, 397–398 (2005). https://doi.org/10.1038/nbt0405-397
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt0405-397
This article is cited by
-
First integrin inhibitor since Tysabri nears approval for IBD
Nature Biotechnology (2014)
-
RNAi-based therapeutic strategies for metabolic disease
Nature Reviews Endocrinology (2011)
-
PML problems loom for Rituxan
Nature Biotechnology (2010)
-
Tysabri's troubles return
Nature Biotechnology (2008)
-
Tysabri back on market
Nature Biotechnology (2006)